Comparison of Plasma Metagenomic Next-generation Sequencing and PCR Methods for Epstein–Barr Virus Viral Load Monitoring in Nasopharyngeal Carcinoma
Anticancer Research · 2024
DOI: 10.21873/anticanres.17370 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Anticancer Research, 2024. Verfasst von Harish N Vasudevan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of California, San Francisco, CA, U.S.A. Hauptthemen laut MEDLINE: Herpesvirus 4, Human, Viral Load, Nasopharyngeal Carcinoma, High-Throughput Nucleotide Sequencing. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
BACKGROUND/AIM: Plasma Epstein-Barr virus (EBV) viral load measurement is prognostic in nasopharyngeal carcinoma (NPC) disease monitoring; however, a consensus measurement approach does not exist. This study characterized the clinical performance of metagenomic next-generation sequencing (mNGS), an unbiased sequencing-based assay distinct from polymerase chain reaction (PCR) or targeted sequencing approaches, in 73 peripheral blood specimens from 32 patients diagnosed with NPC. PATIENTS AND METHODS: Samples were analyzed for plasma EBV viral load either by mNGS profiling or PCR-based assays (either LMP2 or BAMHI-W PCR) and compared to tumor presence by clinical assessment. Plasma mNGS-based EBV detection was quantified as reads per million (RPM). RESULTS: Plasma mNGS displayed similar overall performance (100% sensitivity, 86% specificity, 92% accuracy) to BAMHI-W PCR (100% sensitivity, 86% specificity, 94% accuracy) and superior performance to the LMP2 PCR assay (36% sensitivity, 56% specificity, 45% accuracy). In a subset of 13 patients who underwent longitudinal analysis, plasma mNGS EBV RPM correlated with cancer recurrence (95%CI Pre-CRT=232.10±214; 95%CI Post-CRT=0.34±0.32; 95%CI difference=-231.70±214; *p=0.03, paired t-test), suggesting plasma mNGS exhibits potential for monitoring recurrence. CONCLUSION: Plasma mNGS is a distinct method for EBV titer measurement in NPC patients and more broadly, is a promising method for non-invasive monitoring of disease status for infection-associated malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, University of California, San Francisco, CA, U.S.A.
- Division of Oral Epidemiology and Division of Biostatistics, University of California, San Francisco, CA, U.S.A.
- Department of Laboratory Medicine, University of California, San Francisco, CA, U.S.A.
- Department of Radiation Oncology, University of California, San Francisco, CA, U.S.A.; Sue.Yom@ucsf.edu.
Zitieren
APA
Vasudevan, H. N., Lazar, A. A., Reyes, K., Rong, D. A., Arevalo, S., Federman, S., Chan, J. W., Chiu, C. Y., Miller, S., & Yom, S. S. (2024). Comparison of Plasma Metagenomic Next-generation Sequencing and PCR Methods for Epstein–Barr Virus Viral Load Monitoring in Nasopharyngeal Carcinoma. Anticancer Research. https://doi.org/10.21873/anticanres.17370
Vancouver
Vasudevan HN, Lazar AA, Reyes K, Rong DA, Arevalo S, Federman S, et al. Comparison of Plasma Metagenomic Next-generation Sequencing and PCR Methods for Epstein–Barr Virus Viral Load Monitoring in Nasopharyngeal Carcinoma. Anticancer Research. 2024. doi:10.21873/anticanres.17370
BibTeX
@article{Vasudevan2024,
author = {Vasudevan, Harish N and Lazar, Ann A and Reyes, Kevin and Rong, D A and Arevalo, Shaun and Federman, Scot and Chan, Jason W and Chiu, Charles Y and Miller, Steve and Yom, Sue S},
title = {Comparison of Plasma Metagenomic Next-generation Sequencing and PCR Methods for Epstein–Barr Virus Viral Load Monitoring in Nasopharyngeal Carcinoma},
journal = {Anticancer Research},
year = {2024},
doi = {10.21873/anticanres.17370}
}
EUVIMED